Eli Lilly has ratcheted up its international fight with Canada over what it considers unfair patent rulings. The Indianapolis, IN-based Lilly has now filed a $500 million lawsuit against the Canadian government alleging its patent laws are inconsistent and permitted generics of some of Lilly's drugs to hit the market sooner than they should have.
In the ongoing hunt to uncover new therapies for rare diseases, the NIH has selected four new preclinical drug development studies to support, the findings of which will be shared with other researchers.
Dako got hit with an FDA citation over what the agency says are quality system manufacturing violations involving one of its signature breast cancer diagnostic kits and other related products.
In 2010, Amed Villa was part of a brassy warehouse heist that stunned the industry. Villa and others broke into an Eli Lilly warehouse in Connecticut and drove away in the middle of the night with about $90 million worth of Lilly drugs. But Villa now acknowledges he had practice ripping off drug companies.
After big gains in its stock price, Biodel shares slipped more than 20% this morning on the back of mid-stage trial results for its fast-acting, mealtime insulin candidate.
Even the smallest biotech company can benefit when it thinks and acts globally. And a biotech startup that was able to grab a promising therapeutic asset from Pfizer as it shuttered much of its work in the U.K. has pieced together a global virtual organization that illustrates just how effective that can be.
Eli Lilly's fight to extend Alimta exclusivity will drag into next year. As Reuters reports, a patent trial may have wrapped up last week, but both sides plan to file additional briefs through mid-December. At stake: 5 additional years of exclusivity on the blockbuster lung cancer treatment.
Eli Lilly's success with Alimta has been a boon for Princeton University, which holds a key patent on the drug compound. But because of the university's $524 million in licensing income from the cancer drug, residents of Princeton, NJ, have sued the city government and the school, challenging its tax-exempt status.
The recent, and very public, Chinese investigation into bribery allegations against GlaxoSmithKline and others has doctors running scared, making it tough for everyone to sell drugs there.
ImmunoGen says it's struck a $200 million deal to collaborate with Eli Lilly ($LLY) on developing new armed antibodies.